// App-Quantinova.ai

: Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.

Researchers

Presenter

  • Alan Haruo Bryce

Principal Investigators

  • M. Neil Reaume

  • Peter James Ostler

  • Raymond S. McDermott

  • Joel Roger Gingerich

  • Elias Pintus

  • Srikala S. Sridhar

  • Wassim Abida

  • Gedske Daugaard

  • Axel Heidenreich

  • Laurence E. M. Krieger

  • Brieuc Sautois

  • Andrea Loehr

  • Darrin Despain

  • Jowell Go

  • Simon Paul Watkins

  • Simon Chowdhury

  • Charles J. Ryan

  • Karim Fizazi

Medical Centers

  • University Hospital of Copenhagen Rigshospitalet, Copenhagen, Denmark

  • Clovis Oncology, Inc., Boulder, CO

  • University of Minnesota, Minneapolis, MN

  • Genesis Care, North Shore, Sydney, NSW, Australia

  • Gustave Roussy Institute, Paris-Saclay University, Villejuif, France

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • St Vincents University Hospital and Cancer Trials Ireland, Dublin, Ireland

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Guy's Hospital, London, United Kingdom

  • Mayo Clinic, Phoenix, AZ

  • Univsklinikum Koeln, Cologne, Germany

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Clovis Oncology, Inc., Cambridge, United Kingdom

  • Institut d'Investigació Biomèdica de Bellvitge-Centro de Investigación Biomédica en Red de Oncología, Institut Català d'Oncologia, Barcelona, Spain

  • Cancer Care Manitoba, Winnipeg, MB, Canada

  • Guys Hospital and Sarah Cannon Research Institute, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University Hospital of Liège, CHU Sart-Tilman, Liège, Belgium

Locations

  • Belgium

  • Germany

  • Denmark

  • France

  • Canada

  • Spain

  • Australia

  • Ireland

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • BRCA mutation

  • Apoptotic body index

Drug/Treatment

  • Rucaparib

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02975934

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved